( N Engl J Med 2013; 368: 924–35) aimed to evaluate the efficacy and safety of omalizumab (an IgE monoclonal antibody) in patients with moderate‐to‐severe chronic idiopathic urticaria who remain symptomatic despite H1‐antihistamine therapy at licensed doses. Setting and design Phase 3 ...